NANOCO GROUP PLC — Director's Dealing 2015

Nov 17, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0435G

Nanoco Group PLC

17 November 2015

17 November 2015 

NANOCO GROUP PLC

("Nanoco" or the "Company") 

Director/PDMR Shareholding

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, is issuing the following notification in accordance with DTR 3.1.2.R.

The Company has been notified that on 17 November 2015, Dr Michael Edelman, Chief Executive Officer of Nanoco, sold 1,357,025 ordinary shares of £0.10 each in the Company ("Ordinary Shares") at an average price of 44.2 pence per share. The reason for the share sale is to satisfy tax and other financial commitments associated with Dr Edelman's relocation to the USA.

In addition to the share sale, the Company has been notified that on 17 November 2015, Dr Edelman also transferred 200,000 Ordinary Shares (for nil consideration) as a charitable donation.

Following the transaction, Dr Edelman is interested in 5,431,615 Ordinary Shares, representing 2.29% per cent of the Company's issued share capital.

For further information, please contact:

Nanoco	Tel: +44 (0) 161 603 7900
Michael Edelman, Chief Executive Officer
David Blain, Chief Financial Officer Caroline Watson, Investor Relations Manager cwatson@nanocotechnologies.com	Tel: + 44 (0) 7799 897357
Canaccord Genuity - Joint Broker	Tel: +44 (0) 20 7523 8000
Simon Bridges Cameron Duncan
Mark Whitmore
Liberum - Joint Broker	Tel: +44 (0) 20 3100 2000
Neil Patel
Richard Bootle Steven Tredget
Buchanan	Tel: +44 (0) 20 7466 5000
Mark Court / Sophie Cowles / Stephanie Watson

Notes for editors:

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nano-materials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

Nanoco is listed on the main market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSGMMMMKNDGKZM

//<![CDATA[$.ajaxSetup({headers: {'__RequestVerificationToken':'0JC-8SrbDXTIR-QhGGNEI6_nf_JIEzmvzv9mfyh7r1gn1X88YpUTe0fFioy7bM2KP5I3kx5dps2dKt3pHL4RQRxCpZXywXufq-8zjJQx0rA1:H34KYGy2ppi776iHF4eS3dOXZmC-g2VQHA_YnlYIAIVatk23DHBV-FJX0nV9R_Vnq5DvBNuGIoIgJZXU8pVvAvxhHxm7WWwM4esqzOBN_T01'}});//]]>